Belimumab Assessment of Safety in SLE
NCT01705977
·
clinicaltrials.gov ↗
PHASE4
Phase
COMPLETED
Status
4019
Enrollment
INDUSTRY
Sponsor class
Conditions
Systemic Lupus Erythematosus
Interventions
BIOLOGICAL:
Placebo plus standard therapy
BIOLOGICAL:
Belimumab 10 mg/kg plus standard therapy
OTHER:
Standard therapy
Sponsor
GlaxoSmithKline